Kenya  has been a recipient country of the Global Fund since 2002 and has been disbursed over US$1.5 billion for HIV, TB and malaria. Kenya is part of the Multicountry Africa ECSA-HC, Multicountry Eastern Africa IGAD, Multicountry Eastern Africa KANCO, Multicountry Southern Africa ARASA and  Multicountry TB WC Africa NTP/SRL grants. Kenya is one of the Global Fund’s ‘high impact’ countries. Approximately 60% of Global Fund grants to Kenya are spent on procuring medicines and health products.

With the support of the Global Fund, in Kenya;

• Between 2010 and 2020, the number of AIDS-related deaths annually decreased from approximately 53,000 to 19,000.
• The number of people living with HIV receiving antiretroviral treatment increased from 31% in 2010 to 86% in 2020.
• Coverage of medication that prevents mother to-child transmission of HIV increased from 55% in 2010 to 94% in 2020.
• TB treatment coverage increased from 45% in 2010 to 60% in 2019.
• Strong collaboration between TB and HIV service delivery has resulted in nearly universal screening and treatment of TB/HIV co-infected patients. In 2020, 98% of TB patients knew their HIV status and 97% of TB patients that tested positive for HIV were on antiretroviral therapy during TB treatment.
• Kenya has successfully implemented three long-lasting insecticidal net campaigns since 2014, with more than 42 million mosquito nets distributed to protect people from malaria.

Kenya is part of the the Breaking Down Barriers Initiative which was initiated in 2020, as  part of the operationalisation of Strategic Objective 3 of the Global Fund Strategy 2017 – 2022. As part of this initiative, a Baseline Assessment was conducted in 2021 in Kenya. 

Kenya is one of the five African countries that co-hosted the Preparatory Meeting of the Seventh Replenishment of the Global Fund. Kenya is also a donor to the Global Fund and an implementer of Global Fund-supported programs and has contributed KES 653,550 and US$11 million to the Global Fund to date. The country pledged US$6 million for the Global Fund’s Sixth Replenishment, covering 2020-2022. 

Since 2010, Takeda Pharmaceutical Company Limited has partnered with the Global Fund in Kenya. The partnership works to improve maternal and child health by integrating quality HIV, TB and malaria services in antenatal and postnatal care across the country as well as in Nigeria and Tanzania. In 2022, it is estimated that the project will train 500 health workers at 61 facilities serving 45,000 pregnant women in Kenya alone (Learn more).